Using a Modern Risk Management Tool to Meet ICH E6 Requirements in Clinical Trials
An article examining recent GMP inspection data from two prominent regulatory bodies notes that “Deficiencies in investigations remains at the top of this list over the past four years. We as an industry cannot seem to get this quite right.” I agree. Here’s why.
